KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $24.9 million.

  • Inovio Pharmaceuticals' Cash from Financing Activities rose 367240.3% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.1 million, marking a year-over-year increase of 12782.14%. This contributed to the annual value of $51.5 million for FY2024, which is 93052.1% up from last year.
  • Inovio Pharmaceuticals' Cash from Financing Activities amounted to $24.9 million in Q3 2025, which was up 367240.3% from -$34777.0 recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Cash from Financing Activities ranged from a high of $160.9 million in Q1 2021 and a low of -$11.4 million during Q1 2024
  • In the last 5 years, Inovio Pharmaceuticals' Cash from Financing Activities had a median value of $3.4 million in 2021 and averaged $19.8 million.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Cash from Financing Activities crashed by 257577.3% in 2024, and later surged by 367240.3% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $47.6 million in 2021, then plummeted by 85.99% to $6.7 million in 2022, then crashed by 72.43% to $1.8 million in 2023, then skyrocketed by 1485.47% to $29.1 million in 2024, then dropped by 14.49% to $24.9 million in 2025.
  • Its last three reported values are $24.9 million in Q3 2025, -$34777.0 for Q2 2025, and $1.0 million during Q1 2025.